

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

Date of mailing (day/month/year)
25 June 2001 (25.06.01)

International application No.
PCT/EP00/08910

Applicant's or agent's file reference
80275/WO

International filing date (day/month/year)
12 September 2000 (12.09.00)

Priority date (day/month/year)
29 September 1999 (29.09.99)

Applicant

KUSLYS, Martinas et al

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
11 April 2001 (11.04.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Nestor Santesso

Telephone No.: (41-22) 338.83.38

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

| | |
|---|--|
| To: STRAUS, Alexander BECKER, KURIG, STRAUS Bavariastrasse 7 80336 München ALLEMAGNE | <div style="border: 1px solid black; padding: 2px; font-weight: bold; font-size: 1.2em;">BECKER KURIG STRAUS</div> <div style="border: 1px solid black; padding: 2px; font-size: 0.8em;">BAVARIASTRASSE 7 · 80336 MÜNCHEN</div> <div style="border: 1px solid black; padding: 10px; margin-top: 10px; font-size: 1.5em; font-weight: bold;">14. Dez. 2001</div> <div style="border: 1px solid black; padding: 2px; margin-top: 5px;"> WV: / LF: </div> |
|---|--|

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

| | |
|-------------------------------------|------------|
| Date of mailing (day/month/year) | 14.12.2001 |
|-------------------------------------|------------|

| | |
|---|------------------------|
| Applicant's or agent's file reference 80275/WO | IMPORTANT NOTIFICATION |
|---|------------------------|

| | | |
|---|--|--|
| International application No. PCT/EP00/08910 | International filing date (day/month/year) 12/09/2000 | Priority date (day/month/year) 29/09/1999 |
|---|--|--|

| |
|--|
| Applicant SOCIETE DES PRODUITS NESTLE S.A. et al. |
|--|

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

| | |
|--|---|
| Name and mailing address of the IPEA/ <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 </div> </div> | Authorized officer Longo, E Tel. +49 89 2399-8141 |
|--|---|



THIS PAGE BLANK (USPTO)

REC'D 18 DEC 2001

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

12

| | | |
|--|---|--|
| Applicant's or agent's file reference 80275/WO | FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) | |
| International application No. PCT/EP00/08910 | International filing date (day/month/year) 12/09/2000 | Priority date (day/month/year) 29/09/1999 |
| International Patent Classification (IPC) or national classification and IPC A23L1/29 | | |
| Applicant SOCIETE DES PRODUITS NESTLE S.A. et al. | | |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

| | |
|---|---|
| Date of submission of the demand 11/04/2001 | Date of completion of this report 14.12.2001 |
| Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 | Authorized officer Baminger, U Telephone No. +49 89 2399 2176 |



THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/08910

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-9 as originally filed

Claims, No.:

1-12 as received on 25/10/2001 with letter of 24/10/2001

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/08910

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 10 and 12 .

because:

☒ the said international application, or the said claims Nos. 12 (industrial applicability) relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 10 are so unclear that no meaningful opinion could be formed (*specify*):
see separate sheet

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-9 and 11-12
 No: Claims

Inventive step (IS) Yes: Claims 1-9 and 11-12
 No: Claims

Industrial applicability (IA) Yes: Claims 1-9 and 11

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/08910

No: Claims

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/08910

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

- 3.1 Essential features are missing in claim 10 of the present application. The method of producing the compositions presently claimed is not fully characterized, since no reference is made to the removal of the caseino-glyco-macropeptide. This leads to a serious lack of clarity (Art. 6 PCT) of claim 10 to the extent that no meaningful opinion on the novelty, inventive step or industrial applicability of this claim can be formed.
- 3.2 Claim 12 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: EP-A-0 418 593
D2: JP 58 165742

- 5.1 The subject-matter of claim 1 is novel (Article 33(2) PCT) in view of the prior art available to the examiner.
- 5.2 For the purpose of examining the inventive step of claim 1, D1 can be regarded as the closest prior art. The problem to be solved by the present application appears to lie in the provision of a nutritional composition for an infant formula that contains whey and has an amino acid profile which is close to human mothers milk (cf. description of the present application p. 2, line 35 - p. 3, line 3 and p. 3, lines 11-

THIS PAGE BLANK (USPTO)

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/08910

15). The solution found in claim 1 of the present application lies in the use of a modified whey protein, of which the glyco-macro-peptide has been removed to reduced the threonine content. There is no indication in the prior art to arrive at this solution. Therefore the subject-matter of claim 1 can be considered inventive according to Art. 33 (3) PCT.

5.3 The same arguments apply mutatis mutandis to claims 11-12.

5.4 For the assessment of the present claim 12 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also depend on the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item VIII

Certain observations on the international application

Amended claim 12 contains an error. Claim 12 should refer to claims 1-9 only, since the amended claim 10 is not a composition.

THIS PAGE BLANK (USPTO)

Amended claims

1. A composition for an infant formula which comprises whey protein, wherein the whey protein is acid or sweet whey protein from which caseino-glyco-macropeptide has been removed; casein protein; free arginine; free histidine; ~~and~~ tryptophan rich milk protein, free tryptophan or a mixture thereof.
- 2 ~~3~~. A composition according to claim 1 ~~or 2~~ which comprises from about 9.0 to about 10.0 w/w% of protein
- 3 ~~4~~. A composition according to any preceding claim which comprises about 1.5% to about 3% by weight of arginine; tryptophan and histidine.
- 4 ~~5~~. A composition according to any preceding claim which comprises a lipid source, a carbohydrate source, and a protein source.
- 5 ~~6~~. A composition according to any preceding claim which comprises whey protein which is non-hydrolysed.
- 6 ~~7~~. A composition according to any preceding claim wherein the sweet whey protein is substantially free of lactose.
- 7 ~~8~~. A composition according to any preceding claim which comprises about 6% to about 50% by weight of whey protein and about 20% to about 40% casein protein.
- 8 ~~9~~. A composition according to any preceding claim which comprises about 0% to about 0.1% by weight histidine, about 0.1% to about 0.3% by weight arginine, and about 0.3 to about 0.5% by weight tryptophan.
- 9 ~~10~~. A composition according to any preceding claim which comprises about 0.2% to about 0.4% by weight histidine, about 1% to about 2% by weight arginine, and about 0.2% to about 0.4% by weight tyrtophan.

THIS PAGE BLANK (USPTO)

- ~~10~~ ~~11~~. A method of producing a composition according to any preceding claim which comprises the step of blending whey protein and casein protein together with free arginine; free histidine; and tryptophan rich milk protein, free tryptophan or a mixture thereof and homogenising the blended mixture.
- ~~11~~ ~~12~~. Use of a composition according to any one of claims 1 to ~~10~~⁹ in the manufacture of a medicament or nutritional product for addressing malnutrition.
- ~~12~~ ~~13~~. A method of addressing malnutrition which comprises administering an effective amount of a composition according to any one of claims 1 to 10.

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/22837 A1

(51) International Patent Classification⁷: A23L 1/29,
1/305, 1/30, 1/09

[CZ/CH]; Au Rattalez, CH-1613 Maraçon (CH). MEIS-
TER, Niklaus [CH/CH]; Scherpfenweg 7, CH-3506
Grosshöchstetten (CH).

(21) International Application Number: PCT/EP00/08910

(22) International Filing Date:
12 September 2000 (12.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9923048.4 29 September 1999 (29.09.1999) GB

(71) Applicant (for all designated States except US): SOCI-
ETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box
353, CH-1800 Vevey (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KUSLYS, Martinas
[CH/CH]; Moosackerweg 2B, CH-3506 Grosshöchstetten
(CH). SECRETIN, Marie-Christine [FR/CH]; Ch. du
Dévin 11, Les Chevalleyres, CH-1807 Blonay (CH). JOST,
Rolf [CH/CH]; Bolligenstrasse 71, CH-3065 Bolligen
(CH). MAIRE, Jean-Claude [CH/CH]; 1, ch. de Rueyres,
CH-1092 Belmont S/Lausanne (CH). BALLEVRE,
Olivier [FR/CH]; Rte de Cojonex 16B, CH-1000 Lau-
sanne 25 (CH). HASCHKE, Ferdinand [AT/CH]; Route
de Lavaux 254, CH-1095 Lutry (CH). KRATKY, Zdenek

(74) Agent: BECKER, KURIG, STRAUS; Bavariastrasse 7,
80336 München (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/22837 A1

(54) Title: COMPOSITION COMPRISING CASEIN PROTEIN AND WHEY PROTEIN

(57) Abstract: A composition for an infant formula which comprises casein protein and whey protein; a method of producing the composition; use of the composition in the manufacture of a medicament or nutritional product for addressing malnutrition; and a method of addressing malnutrition which comprises administering an effective amount of the composition. A preferred embodiment of the composition comprises non-hydrolysed protein, free arginine; tryptophan and histidine, a lipid source and a carbohydrate source. In addition, the whey protein is acid whey protein or sweet whey protein from which caseino-glycomacropeptide has been removed.

THIS PAGE BLANK (USPTO)

Composition Comprising Casein Protein & Whey Protein

This invention relates to a composition for an infant formula which comprises casein protein and whey protein; a method of producing the composition; use of
5 the composition in the manufacture of a medicament or nutritional product for addressing malnutrition; and a method of addressing malnutrition which comprises administering an effective amount of the composition.

10 Within the context of this application the word "comprises" is taken to mean "includes, among other things" and it is not intended to mean "consists of only".

Mother's milk is recommended for all infants. However, in some cases mother's milk is not available and infant formulae must be used. Normal, full-term infants are usually fed cow's-milk-based formulas. These formulas contain a mixture of
15 casein and whey as protein sources and they provide nutrition for infants, however they do not provide a protein concentration and an amino acid profile equivalent to that of mother's milk. In addition these standard formulae are not suitable for pre-term infants and those having adverse reactions to protein in cow's milk formula or to lactose.

20 An alternatives to cow's milk formula is soy formula; particularly for infants who are lactose intolerant. However, soy is not as good a protein source as cow's milk. Also, infants do not absorb some minerals, such as calcium, as efficiently from soy formulae.

25 A further alternative formula is based on hydrolysed protein. These formulas are hypoallergenic and have a decreased likelihood of an allergic reaction.

Ideally, to be as close as possible to human milk, the protein in infant formulae
30 may be derived from both whey and casein in an appropriate ratio. However, a problem with conventional formulae having these proteins is that they have a high protein concentration to ensure that the infant gets the necessary amount of all essential amino acids. The protein concentration is higher than the concentration normally found in human milk and it may not be beneficial for an
35 infant because an infant's metabolism is susceptible to overloading with nitrogen from its protein intake.

To address this problem, formulae having improved amino acid profiles have been suggested, for example those having hydrolysed whey proteins. The whey protein may be acid whey protein or sweet whey protein. In general, acid whey protein is preferred from a nutritional point of view since it has a lower threonine content and this is closer to that of human milk. However, until now it has not been possible to provide the advantage of a composition having a protein concentration equivalent to the concentration in human milk and a good amino acid profile in formulae having whey protein and casein. An advantage provided by casein in formulae is that it has the ability to form curd which enhances the feeling of satiety.

The present invention addresses the problems set out above.

Accordingly, the invention provides a composition for an infant formula which comprises whey protein; casein protein; free arginine; free histidine; and tryptophan rich milk protein, free tryptophan or a mixture thereof.

In a second aspect the invention provides a method of producing the composition which comprises the step of blending whey protein and casein protein together with free arginine; free histidine; and tryptophan rich milk protein, free tryptophan or a mixture thereof and homogenising the blended mixture.

In a third aspect the invention provides use of an embodiment of the composition in the manufacture of a medicament or nutritional product for addressing malnutrition.

In a forth aspect the invention provides a method of addressing malnutrition which comprises administering an effective amount of an embodiment of the composition.

Preferably, tryptophan rich milk protein has a level of about 5% or more of amino acids as tryptophan. More preferably it is about 10% or more.

Preferably, the whey protein is acid whey protein or sweet whey protein from which caseino-glyco-macropetide has been removed. This provides the

advantage of a reduced threonine content and an increased tryptophan content as compared to normal sweet whey and is therefore suitable as a protein source for infants.

5 Preferably an embodiment of the composition comprises from about 9.0 to about 10.0 w/w% of protein, more preferably about 9.5% w/w%. This corresponds to about 1.8g protein /100kcal. An advantage provided by this concentration of protein is that it is equivalent to the amount of protein generally present in human milk and it corresponds to the lower limit tolerated by codex alimentarius.

10 Preferably an embodiment of the composition comprises about 0.5% to about 3% by weight of arginine; tryptophan and histidine. Suprisingly, it has been found that by supplementing the sweet whey fraction with the free amino acids arginine, tyrosine, and histidine, the protein source has an amino acid profile
15 which is close to that of human milk.

Preferably an embodiment of the composition comprises a lipid source, a carbohydrate source, and a protein source. This provides the advantage that the composition is as close as possible in content to mothers milk.

20 Preferably an embodiment of the composition comprises whey protein which is non-hydrolysed. In alternative embodiments it is hydrolysed.

25 Preferably, the sweet whey fraction is substantially free of lactose. This has the advantage that the infant formula has reduced levels of lysine blockage.

30 Preferably an embodiment of the composition comprises about 6% to about 50% by weight of whey protein, more preferably about 20% to 40% whey protein, most preferably 30% whey protein. Preferably it comprises from about 20% to about 40% casein protein, more preferably about 30%. Most preferably, the ratio of whey protein to casein protein is about 60%:about 40% to about 70%:about 30%.

35 Preferably the free amino acids are in free base form.

In one embodiment the composition is suitable for a pre-term infant formula and comprises about 0% to about 0.1% by weight histidine, about 0.1% to about 0.3% by weight arginine, and about 0.3 to about 0.5% by weight tryptophan.

- 5 In an alternative embodiment the composition is suitable for a full-term, hypoallergenic infant formula in which the protein source preferably comprises about 0.2% to about 0.4% by weight histidine, about 1% to about 2% by weight arginine, and about 0.2% to about 0.4% by weight tryptophan.
- 10 Preferably the concentration of tryptophan in the composition is at least about 135mg/g and the concentration of threonine in the composition is less than about 350mg/g. Preferably the threonine concentration corresponds to about 4.9 g per 100g protein to about 5.1g per 100g protein.
- 15 The carbohydrate source may include lactose. The lactose may be the sole source of carbohydrates.

Embodiments of the invention are now described by way of example.

- 20 The invention provides a composition for an infant formula which comprises arginine, tryptophan, histidine and a sweet whey fraction from which caseino-glyco-macropptide has been removed. The infant formula may be used for pre-term or full-term infants.
- 25 The sweet whey used in the protein source may be obtained from cheese making, particularly the sweet whey obtained after the coagulation of casein by rennet. The sweet whey may then be processed as desired. For example, the sweet whey may be treated to remove minerals (cations, anions), lactose, or any of these substances. The sweet whey may be concentrated as desired. Suitable sweet
- 30 whey sources are commercially available. It is particularly preferred that the sweet whey is substantially lactose-free.

- The sweet whey is then treated to remove caseino-glyco-macropptide. This may be accomplished by any suitable process. One suitable process is described in
- 35 European patent application 0880902, the disclosure of which is incorporated by reference. In this process, the pH of the sweet whey is adjusted to 1 to 4.3, if

necessary. The sweet whey is then contacted with a weakly anionic resin which is predominantly alkaline until the pH of the sweet whey stabilises at about 4.5 to 5.5. The sweet whey fraction from which the caseino-glyco-macropetide has been removed, is then collected.

5

In an embodiment of the composition the whey protein is non-hydrolysed. In an alternative embodiment, the sweet whey fraction is hydrolysed to prevent allergic reactions in infants at risk and to make the protein easier to digest. The hydrolysis process may be carried out as desired and as is known in the art. In general, the whey protein hydrolysate is prepared by enzymatically hydrolysing the sweet whey fraction in one or more steps. For example, for an extensively hydrolysed protein, the sweet whey proteins may be subjected to triple hydrolysis using, for example, Alcalase 2.4L (EC 940459), then Neutrase 0.5L (obtainable from Novo Nordisk Ferment AG) and then pancreatin at 55°C. Alternatively, for a less hydrolysed protein, the sweet whey may be subjected to double hydrolysis using, for example, NOVOZYMES and then pancreatin.

10

15

If the sweet whey fraction used is substantially lactose free, it is found that the protein is subjected to much less lysine blockage during the hydrolysis process. This enables the extent of lysine blockage to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example about 7% by weight of lysine. This greatly improves the nutritional quality of the protein source.

20

The free amino acids L-arginine, L-tyrptophan and L-histidine are included in the protein source. Preferably, they are in the form of free amino acids and make up about 1.5% to about 3% by weight of the protein source. For example, the free amino acids may make up about 2% to about 2.6% by weight of the protein source.

25

30

In particular, for pre-term formulas, histidine preferably provides about 1% to about 1.5% by weight, arginine preferably provides about 0.6% to about 0.9% by weight, and tyrptophan preferably provides about 0.3% to about 0.5% by weight, of the protein source. For hypoallergenic formulas, histidine preferably provides about 0.2% to about 0.4% by weight, arginine preferably provides about 1% to

35

about 2% by weight, and tyrtophan preferably provides about 0.2% to about 0.4% by weight, of the protein source.

The protein source may include other free amino acids as desired.

The carbohydrate source in the infant formula can be carbohydrate suitable for use in infant formulas. Preferred carbohydrate sources are selected from the group which comprises sucrose, maltodextrin, maltose, lactose, corn syrup, corn syrup solids, rice syrup solids, rice starch, and the like. Preferably, the carbohydrate source includes lactose and maltodextrin. The lactose is preferably free of any allergens. For full term formulas, the carbohydrate source is preferably lactose.

The lipid source may be any lipid or fat which is suitable for use in infant formulas. Preferred lipid sources include milk fat, safflower oil, egg yolk lipid, canola oil, olive oil, coconut oil, palm oil, palm kernel oil, palm olein, soybean oil, sunflower oil, fish oil, and microbial fermentation oil containing long-chain, polyunsaturated fatty acids. These oils may be in the form of high oleic forms such as high oleic sunflower oil and high oleic safflower oil. The lipid source may also be in the form of fractions derived from these oils such as palm olein, medium chain triglycerides (MCT), and esters of fatty acids such as arachidonic acid, linoleic acid, palmitic acid, stearic acid, docosahexaenoic acid, linolenic acid, oleic acid, lauric acid, capric acid, caprylic acid, caproic acid, and the like.

For pre-term formulas, the lipid source preferably contains medium chain triglycerides; for example in an amount of about 15% to about 35% by weight of the lipid source.

The lipid source preferably has a ratio of n-6 to n-3 fatty acids of about 5:1 to about 15:1; for example about 8:1 to about 10:1.

The infant formula may further comprise ingredients which are designed to meet the nutritional needs of a human infant. In particular, it is preferred that the infant formula is "nutritionally complete"; that is it contains adequate nutrients to sustain healthy human life for extended periods.

The amount of protein per 100 kcal of formula is typically about 1.8g to about 4.5 g; for example about 1.8 g to about 4 g. For full term hypoallergenic formulas, the amount may be about 1.8 g/100 kcal to about 2.5 g/100 kcal. In order to reduce protein loading, the amount may be less than about 2 g/100 kcal. For pre-term formulas, the amount may be about 2.5 g/100 kcal to about 4 g/100 kcal.

The amount of lipid source per 100 kcal of formula may be about 3.3 g to about 6.5 g; for example about 4.4 g to about 6.5g. The amount of carbohydrate source per 100 kcal of total formula is typically about 7 g to about 14 g.

When in nutritionally complete form, the infant formula contains all vitamins and minerals understood to be essential in the daily diet and in nutritionally significant amounts. Minimum requirements have been established for certain vitamins and minerals. Examples of minerals, vitamins and other nutrients optionally present in the infant formula include vitamin A, vitamin B₁, vitamin B₂, vitamin B₆, vitamin B₁₂, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorous, iodine, iron, magnesium, copper, zinc, manganese, chloride, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are usually added in salt form. The presence and amounts of specific minerals and other vitamins will vary depending on the intended infant population.

If necessary, the infant formula may contain emulsifiers and stabilisers such as soy lecithin, citric acid esters of mono- and di-glycerides, and the like. This is especially the case if the formula is provided in liquid form.

The infant formula may optionally contain other substances which may have a beneficial effect such as fibres, lactoferrin, nucleotides, nucleosides, and the like.

The infant formula may be prepared in any suitable manner. For example, for an infant formula may be prepared by blending together the protein source, the carbohydrate source, and the fat source in appropriate proportions. If used, the emulsifiers may be included in the blend. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source

prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.

5 The liquid mixture may then be thermally treated to reduce bacterial loads. For example, the liquid mixture may be rapidly heated to a temperature in the range of about 80°C to about 110°C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.

10 The liquid mixture may then be cooled to about 60°C to about 85°C; for example by flash cooling. The liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage. The homogenised mixture may then be
15 further cooled to add any heat sensitive components; such as vitamins and minerals. The pH and solids content of the homogenised mixture is conveniently standardised at this point.

If it is desired to produce a powdered infant formula, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and
20 converted to powder. The powder should have a moisture content of less than about 5% by weight.

If it is desired to produce a liquid infant formula, the homogenised mixture is filled into suitable containers; preferably aseptically. However, the liquid infant
25 formula may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available. The liquid infant formula may be in the form of a ready to feed formula having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids
30 content of about 20 to about 26% by weight.

Specific examples of the invention are now described for illustration.

Example 1

- 35 a) A sweet whey protein concentrate is dissolved in deionised water and the pH is adjusted to 4.25 by contacting the solution with a cation exchange

resin (IMAC HP 1100 E, Rohm and Haas). The solution is treated with a weakly anionic resin (IMAC HP 661, Rohm & Haas, which has been regenerated in OH⁻ form) for about 6 hours at 8°C. Once the pH reaches about 5.25 and does not change, the solution is recovered. Over 85% of the caseino-glyco-macropeptide originally present has been removed from the solution.

- b) The solution of step a) is standardised in demineralised water at 55°C. The solution is then heated to 75°C for 20 seconds. The pH of the solution is adjusted to 7.5 by the addition of Ca(OH)₂ and a solution of NaOH and KOH.

The reaction mixture is then subjected to microfiltration and ultrafiltration and then dried by lyophilisation and packaged into metal cans. The protein has low levels of lysine blockage with 6.9% blocked lysine and 9% reactive lysine.

- c) The protein of step b) is combined with 0.72% by weight L-arginine, 0.44% by weight of L-tyrptophan, and 1.38% by weight of L-histidine. The mixture is formulated into a powdered infant formula. The infant formula has the following composition:

| Component | Amount |
|--|---------------------|
| Milk SNF | 8-10% |
| Whey protein | 6-50% |
| Alpha-lactalbumin rich whey protein source | 0-2% |
| Arginine | 0.1-0.3% |
| Histidine | 0-0.1% |
| Fat | 25-30% |
| Lactose | 10-40% |
| Vitamins and minerals | To meet regulations |

The composition has a protein concentration of 9.5 w/w% or 1.8g protein /100kcal.

Claims

1. A composition for an infant formula which comprises whey protein; casein protein; free arginine; free histidine; and tryptophan rich milk protein, free tryptophan or a mixture thereof.
2. A composition according to claim 1 wherein the whey protein is acid whey protein or sweet whey protein from which caseino-glyco-macropeptide has been removed.
3. A composition according to claim 1 or 2 which comprises from about 9.0 to about 10.0 w/w% of protein
4. A composition according to any preceding claim which comprises about 1.5% to about 3% by weight of arginine; tryptophan and histidine.
5. A composition according to any preceding claim which comprises a lipid source, a carbohydrate source, and a protein source.
6. A composition according to any preceding claim which comprises whey protein which is non-hydrolysed.
7. A composition according to any preceding claim wherein the sweet whey protein is substantially free of lactose.
8. A composition according to any preceding claim which comprises about 6% to about 50% by weight of whey protein and about 20% to about 40% casein protein.
9. A composition according to any preceding claim which comprises about 0% to about 0.1% by weight histidine, about 0.1% to about 0.3% by weight arginine, and about 0.3 to about 0.5% by weight tryptophan.
10. A composition according to any preceding claim which comprises about 0.2% to about 0.4% by weight histidine, about 1% to about 2% by weight arginine, and about 0.2% to about 0.4% by weight tyrtophan.

11. A method of producing a composition according to any preceding claim
which comprises the step of blending whey protein and casein protein
together with free arginine; free histidine; and tryptophan rich milk protein,
5 free tryptophan or a mixture thereof and homogenising the blended mixture.
12. Use of a composition according to any one of claims 1 to 10 in the
manufacture of a medicament or nutritional product for addressing
malnutrition.
- 10 13. A method of addressing malnutrition which comprises administering an
effective amount of a composition according to any one of claims 1 to 10.

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| | | |
|---|---|--|
| Applicant's or agent's file reference 80275/WO | FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below. | |
| International application No. PCT/EP 00/ 08910 | International filing date (day/month/year) 12/09/2000 | (Earliest) Priority Date (day/month/year) 29/09/1999 |
| Applicant SOCIETE DES PRODUITS NESTLE S.A. et al. | | |

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

THIS PAGE BLANK (USPTO)

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08910

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23L1/29 A23L1/305 A23L1/30 A23L1/09

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, FSTA, EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-------------------------------|
| X A | EP 0 418 593 A (MILUPA) 27 March 1991 (1991-03-27) page 2, line 1-3 page 2, line 41 -page 3, line 51 claims 2-6; examples --- | 1,3,5,6, 11,12 2,4,7-10 |
| X A | WO 93 16595 A (ABBOTT LAB) 2 September 1993 (1993-09-02) claims 1,3,10,19; tables 1,3 page 6, line 4 -page 8, line 1 page 11, line 3 -page 12, line 3 --- -/-- | 1,4,5,8, 10-12 2-4,6,7 |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 January 2001

Date of mailing of the international search report

20.02.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Tallgren, A

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08910

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | DATABASE WPI Section Ch, Week 198345 Derwent Publications Ltd., London, GB; Class D13, AN 1983-811409 XP002158762 & JP 58 165742 A (MEIJI MILK PROD CO LTD), 30 September 1983 (1983-09-30) | 1,5,6,8, 12 |
| A | abstract | 2-4,7, 9-11 |
| X | --- WO 98 04254 A (BEALE PAXTON K) 5 February 1998 (1998-02-05) claims 3,23,24,27,28; example 1 page 7, line 20 -page 8, line 12 page 9, line 4-6 | 1,6,8,12 |
| A | page 10, line 4-17 | 2-5,7, 9-11 |
| A | --- EP 0 880 902 A (NESTLÉ PRODUKTE) 2 December 1998 (1998-12-02) cited in the application claims ----- | 2 |

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08910

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|--|--|
| EP 418593 A | 27-03-1991 | AT 96621 T DD 297304 A DE 59003330 D DK 418593 T ES 2062231 T GR 3026131 T PT 95114 A,B TR 24775 A | 15-11-1993 09-01-1992 09-12-1993 13-12-1993 16-12-1994 29-05-1998 18-04-1991 01-05-1992 |
| WO 9316595 A | 02-09-1993 | US 5221668 A AU 3614393 A CA 2128078 A DE 69325091 D DE 69325091 T DK 630181 T EP 0630181 A GR 3030642 T JP 2644086 B JP 7500348 T MX 9300999 A NZ 249392 A | 22-06-1993 13-09-1993 02-09-1993 01-07-1999 23-12-1999 15-11-1999 28-12-1994 29-10-1999 25-08-1997 12-01-1995 01-09-1993 26-01-1996 |
| JP 58165742 A | 30-09-1983 | JP 1670299 C JP 3035896 B | 12-06-1992 29-05-1991 |
| WO 9804254 A | 05-02-1998 | US 5716926 A BR 9710586 A CA 2261708 A CZ 9900249 A EP 0914109 A US 6008252 A US 5889040 A | 10-02-1998 21-03-2000 05-02-1998 16-06-1999 12-05-1999 28-12-1999 30-03-1999 |
| EP 880902 A | 02-12-1998 | AU 8107798 A BR 9809171 A WO 9853702 A EP 0986312 A | 30-12-1998 01-08-2000 03-12-1998 22-03-2000 |

THIS PAGE BLANK (USPTO)